AstraZeneca PLC (LON:AZN)
London
· Delayed Price · Currency is GBP · Price in GBX | Market Cap | 170.58B |
| Revenue (ttm) | 41.24B |
| Net Income (ttm) | 6.05B |
| Shares Out | 1.55B |
| EPS (ttm) | 3.87 |
| PE Ratio | 28.39 |
| Forward PE | 15.13 |
| Dividend | 2.39 (2.17%) |
| Ex-Dividend Date | Aug 7, 2025 |
| Volume | 1,490,962 |
| Average Volume | 1,856,396 |
| Open | 10,900 |
| Previous Close | 10,956 |
| Day's Range | 10,784 - 11,020 |
| 52-Week Range | 9,574 - 12,256 |
| Beta | 0.17 |
| RSI | 35.51 |
| Earnings Date | Nov 6, 2025 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]
Financial Performance
In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.
Financial numbers in USD Financial StatementsNews
Pharma tariffs 'not a huge risk' for domestic companies, says Mizuho's Jared Holz
CNBC's “Fast Money” team discusses the potential impact of pharmaceutical tariffs with Jared Holz, healthcare equity strategist at Mizuho.
A New Prescription For Pain: Understanding Trump's 100% Pharma Tariff
Novo Nordisk, Sanofi, and AstraZeneca face the largest dollar exposure to President Trump's new 100% tariff on imported branded drugs. NVO's heavy reliance on U.S. sales and imported GLP-1 products pu...
AstraZeneca to Offer Discounted Drugs As Trump Pressures Pharma Industry to Cut Prices
AstraZeneca said it will offer its asthma and diabetes drugs at an up to 70% discount in the U.S. ahead of a Trump administration deadline for pharmaceutical companies to cut drug prices.
AstraZeneca launches direct-to-consumer platform to expand access to medications for US patients, including those living with chronic conditions
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announces the launch of AstraZeneca Direct, an online platform designed to create a simple, convenient way for eligible patients to access their pr...
AstraZeneca to cut some direct-to-patient US drug prices after Trump demand
AstraZeneca said on Friday it will sell its diabetes and asthma drugs direct to cash-paying U.S. patients at a discount of up to 70% off list prices, the latest pharma company to do so after pressure ...
AZN, Daiichi's Enhertu sBLA Gets FDA Priority Review for Breast Cancer
AstraZeneca and Daiichi's Enhertu wins FDA priority review in breast cancer, backed by phase III data showing a 44% lower progression risk.
AstraZeneca: Oncology Breakthroughs And Farxiga Surge Excite Investors
Moderna boss defends UK in drug-pricing row as he opens £150m Oxfordshire facility
‘We’re here to invest,’ says Darius Hughes as he calls comments by other pharma companies ‘a little harsh’ The UK boss of the US drugmaker Moderna, which shot to prominence with its Covid vaccine duri...
AstraZeneca (AZN) Receives FDA Priority Review for Enhertu
AstraZeneca (AZN) Receives FDA Priority Review for Enhertu
AstraZeneca, Daiichi Sankyo under priority review of FDA for breast cancer
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab granted Priority Review in the US as 1st-line treatment for patients with HER2-positive metastatic breast cancer
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Daiichi Sankyo's supplemental Biologics License Application (sBLA) for ENHERTU® (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab has ...
AstraZeneca (AZN) Gains Priority Review for Breast Cancer Treatment
AstraZeneca (AZN) Gains Priority Review for Breast Cancer Treatment
AstraZeneca (AZN) Receives Approval for Diagnostic System in Japan
AstraZeneca (AZN) Receives Approval for Diagnostic System in Japan
European Advisory Panel Recommends Two AstraZeneca Drugs For Approval
AstraZeneca Plc (NASDAQ: AZN) and Amgen Inc.'s (NASDAQ: AMGN) Tezspire (tezepelumab) has been recommended for approval in the European Union (EU) for adult patients with chronic rhinosinusitis with ...
European Advisory Panel Recommends Two AstraZeneca Drugs For Approval
AstraZeneca Plc AZN and Amgen Inc.'s AMGN Tezspire (tezepelumab) has been recommended for approval in the European Union (EU) for adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
Is the Market Bullish or Bearish on AstraZeneca?
AstraZeneca's (NYSE: AZN) short interest as a percent of float has risen 25.0% since its last report. According to exchange reported data, there are now 7.77 million shares sold short , which is 0.25...
AstraZeneca (AZN) Expands Partnership to Enhance Cancer Treatment
AstraZeneca (AZN) Expands Partnership to Enhance Cancer Treatment
AstraZeneca (AZN) Gains EU Recommendation for Tezspire in Treating CRSwNP
AstraZeneca (AZN) Gains EU Recommendation for Tezspire in Treating CRSwNP
EU Recommends Approval for AstraZeneca's Koselugo for NF1 Treatment
EU Recommends Approval for AstraZeneca's Koselugo for NF1 Treatment
SOPHiA GENETICS Expands Collaboration with AstraZeneca to Enhance Detection of Breast and Prostate Cancer
BOSTON , Sept. 22, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, today announced an expansion of its collaboration with AstraZeneca (LS...
AstraZeneca’s Koselugo looks set for EU approval
European Medicines Agency's positive response follows results from the KOMET trial and could soon open market for successful treatment.
AstraZeneca: CHMP Recommends Approval Of Tezspire In The EU
(RTTNews) - AstraZeneca and Amgen's Tezspire or tezepelumab has been recommended for approval in the European Union for the treatment of adult patients with chronic rhinosinusitis with nasal polyps. T...
Bloomberg Dividend Watchlist's 4 Ideal 'Safer' September Sizzlers
Bloomberg Intelligence highlights 50 Companies to Watch for 2025, focusing on catalysts like leadership changes, M&A, and sector trends such as AI and EVs. Dogcatcher analysis identifies 13 dividend-p...
Astrazeneca (AZN) Stock Slides as Market Rises: Facts to Know Before You Trade
Astrazeneca (AZN) closed at $76.28 in the latest trading session, marking a -1.03% move from the prior day.
ALEX BRUMMER: Donald Trump's big pharma win
Britain's leading-edge big pharma companies AstraZeneca and GSK are pledging £59billion of investment in the US over the next five years. Spending in Blighty is on hold.